

## Author index\*

### A

- Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrer I, Ford N, Salazar DE. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. 2001;69:95-103  
 Aluri J (see Mould et al). 2001;69:210-22  
 Arai T (see Tsuruoka et al). 2001;69:422-30  
 Arendt-Nielsen L (see Enggaard et al). 2001;69:245-51  
 Asoh M (see Tateishi et al). 2001;69:333-9

### B

- Backman JT (see Kyrklund et al). 2001;69:340-5  
 Backman JT (see Niemi et al). 2001;69:194-200  
 Backman JT (see Niemi et al). 2001;69:400-6  
 Bae KS (see Yu et al). 2001;69:266-73  
 Bailey DG (see Malhotra et al). 2001;69:14-23  
 Barbey JT (see Abernethy et al). 2001;69:95-103  
 Barbey JT (see Saul et al). 2001;69:145-57  
 Beerman L (see Saul et al). 2001;69:145-57  
 Bégaud B (see Lacoste-Roussillon et al). 2001;69:458-62  
 Bégaud B (see Moore et al). 2001;69:445-50  
 Bekersky I (see Mancinelli et al). 2001;69:24-31  
 Benet LZ (see Mancinelli et al). 2001;69:24-31  
 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. 2001;69:89-95 (Commentary)  
 Boger R (see Kovarik et al). 2001;69:48-56  
 Böttiger Y, Säwe J, Brattström C, Tollemar J, Burke JT, Häss G, Zimmerman JJ. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. 2001;69:32-40  
 Brattström C (see Böttiger et al). 2001;69:32-40  
 Brinkmann U (see Cascorbi et al). 2001;69:169-74  
 Brown KS (see Abernethy et al). 2001;69:95-103  
 Bruce MA (see Hamman et al). 2001;69:114-21  
 Brösen K (see Madsen et al). 2001;69:41-7  
 Buaron K (see Gonzales et al). 2001;69:438-44  
 Burggraaf J (see Twiss et al). 2001;69:431-7  
 Burke JT (see Böttiger et al). 2001;69:32-40  
 Busse D, Fromm MF, Mörike K, Drescher S, Kühlkamp V, Eichelbaum M. Disposition and pharmacologic effects of *R/S*-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. 2001;69:324-32

### C

- Cambon N (see Kovarik et al). 2001;69:48-56  
 Carpenter RL (see Liu et al). 2001;69:66-71  
 Carrier S (see Mancinelli et al). 2001;69:24-31  
 Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects. 2001;69:169-74

\*January, pp. 1-88; February, pp. P1-P128; March, pp. 89-188; April, pp. 189-280; May, pp. 281-384; June, pp. 385-482. Index to the ASCPT meeting abstracts is located in the February issue.

- Chapelsky M (see Mould et al). 2001;69:210-22  
 Chien M (see Chiou et al). 2001;69:79-80 (Letter)  
 Chiou WL, Chien M, Chung SM, Wu TC. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol. 2001;69:79-80 (Letter)  
 Cho JY (see Yu et al). 2001;69:266-73  
 Christians U (see Mancinelli et al). 2001;69:24-31  
 Chung C (see Jen et al). 2001;69:407-21  
 Chung SM (see Chiou et al). 2001;69:79-80 (Letter)  
 Clavien PA (see Kovarik et al). 2001;69:201-9  
 Clive S, Jodrell D, Webb D. Gastrin-releasing peptide is a potent vasodilator in humans. 2001;69:252-9  
 Cohen AF (see Twiss et al). 2001;69:431-7  
 Conner BA (see Reidenberg and Conner). 2001;69:189-93 (Commentary)  
 Czaja-Bulsa G (see Gawronska-Szkwarz et al). 2001;69:372-78

### D

- Darné B (see Ragueneau et al). 2001;69:122-9  
 DeBrot DJ (see Goldstein et al). 2001;69:7-13  
 Démolis JL (see Ragueneau et al). 2001;69:122-9  
 den Hartigh J (see Twiss et al). 2001;69:431-7  
 DiMasi JA. New drug development in the United States from 1963 to 1999. 2001;69:286-96  
 DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. 2001;69:297-307  
 Drescher S (see Busse et al). 2001;69:324-32  
 Dressler D (see Mancinelli et al). 2001;69:24-31

### E

- Edmondson A (see Manion et al). 2001;69:346-55  
 Eichelbaum M (see Busse et al). 2001;69:324-32  
 Eichelbaum M (see Cascorbi et al). 2001;69:169-74  
 Enggaard TP, Klitgaard NA, Gram LF, Arendt-Nielsen L, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. 2001;69:245-51  
 Enggaard TP (see Madsen et al). 2001;69:41-7  
 Etter JF, Perneger TV. Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public. 2001;69:175-83  
 Everolimus Phase 2 Study Group (see Kovarik et al). 2001;69:48-56  
 Ezzet F (see Jen et al). 2001;69:407-21

### F

- Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. 2001;69:223-31  
 Feigal DW Jr (see Galuppi et al). 2001;69:387-99  
 Feihl F (see Kubli et al). 2001;69:238-44  
 Feirrer I (see Abernethy et al). 2001;69:95-103  
 Ferry LH (see Gonzales et al). 2001;69:438-44  
 Floren LC (see Mancinelli et al). 2001;69:24-31  
 Ford N (see Abernethy et al). 2001;69:95-103  
 Franc J (see Abernethy et al). 2001;69:95-103

- Frassetto L (see Mancinelli et al). 2001;69:24-31  
 Fricke JR, Jr (see Liu et al). 2001;69:66-71  
 Fromm MF (see Busse et al). 2001;69:324-32  
 Fujimura A (see Harada et al). 2001;69:130-6  
 Fujimura A (see Kawaguchi et al). 2001;69:232-7  
 Fujimura A (see Tsuruoka et al). 2001;69:422-308  
 Fujumura Y (see Kusumoto et al). 2001;69:104-7  
 Funk-Brentano C (see Ragueneau et al). 2001;69:122-9  
 Funk C (see Fattinger et al). 2001;69:223-31  
 Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. 2001;69:158-68  
 Furuyoshi S (see Tsuruoka et al). 2001;69:422-30

## G

- Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. 2001;69:387-99 (Commentary)  
 Gawronska-Szklarz B, Pawlik A, Czaja-Bulsa G, Górnik W, Lusawska-Kutrzeba T, Wrzesniewska J. Genotype of *N*-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy. 2001;69:372-78  
 Gerbeau C (see Kovarik et al). 2001;69:201-9  
 Gerbeau C (see Kovarik et al). 2001;69:48-56  
 Gerloff T (see Cascorbi et al). 2001;69:169-74  
 Glue P (see Jen et al). 2001;69:407-21  
 Goldstein DJ, Sundell KL, DeBrotta DJ, Offen WW. Determination of pregnancy outcome risk rates after exposure to an intervention. 2001;69:7-13 (Commentary)  
 Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, Herrero LA, Krishen A, Sweeney A, Buaron K, Metz A. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. 2001;69:438-44  
 Górnik W (see Gawronska-Szklarz et al). 2001;69:372-78  
 Gram LF (see Enggaard et al). 2001;69:245-51  
 Granett J (see Mould et al). 2001;69:210-22  
 Green MD (see Galluppi et al). 2001;69:387-99  
 Griesmacher A (see Weigel et al). 2001;69:137-44  
 Gupta SK (see Jen et al). 2001;69:407-21

## H

- Haber P (see Schenk et al). 2001;69:365-71  
 Haehner-Daniels BD (see Hamman et al). 2001;69:114-21  
 Hajian G (see Jen et al). 2001;69:407-21  
 Halkin H, Katzir I, Kurman I, Jan J, Malkin BBO. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. 2001;69:260-5  
 Hall ML (see Kovarik et al). 2001;69:201-9  
 Hall SD (see Hamman et al). 2001;69:114-21  
 Hamman, MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. 2001;69:114-21  
 Hanai H (see Furuta et al). 2001;69:158-68  
 Hansen LL (see Madsen et al). 2001;69:41-7  
 Hansson A (see Molander et al). 2001;69:57-65  
 Harada K (see Kawaguchi et al). 2001;69:232-7  
 Harada K, Sugimoto K, Kawaguchi A, Ohmori M, Fujimura A. Effect of angiotensin II on venodilator response to nitroglycerin. 2001;69:130-6  
 Haramburu F (see Lacoste-Roussillon et al). 2001;69:458-62

- Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. 2001;69:308-16  
 Häss G (see Böttiger et al). 2001;69:32-40  
 Hassan F. Being a modern pharmaceutical company: new paradigms for the pharmaceutical industry. 2001;69:281-5 (Commentary)  
 Herrero LA (see Gonzales et al). 2001;69:438-44  
 Hinderling PH (see Saul et al). 2001;69:145-57  
 Hodgson PS (see Liu et al). 2001;69:66-71  
 Hoffmeyer S (see Cascorbi et al). 2001;69:169-74  
 Howard J (see Manion et al). 2001;69:346-55

## I

- Inui K (see Hashida et al). 2001;69:308-16  
 Ishizaki T (see Tanaka et al). 2001;69:108-13  
 Ishizaki T (see Furuta et al). 2001;69:158-68

## J

- Jacobs S (see Jen et al). 2001;69:407-21  
 Jaillon P (see Ragueneau et al). 2001;69:122-9  
 Jamerson BD (see Gonzales et al). 2001;69:438-44  
 Jan J (see Halkin et al). 2001;69:260-5  
 Jang IJ (see Yu et al). 2001;69:266-73  
 Jen JF, Glue P, Ezzet F, Chung C, Gupta SK, Jacobs S, Hajian G. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. 2001;69:407-21  
 Jin J (see Saul et al). 2001;69:145-57  
 Jodrell D (see Clive et al). 2001;69:252-9  
 John A (see Cascorbi et al). 2001;69:169-74

## K

- Kahan BD (see Kovarik et al). 2001;69:48-56  
 Kaneko E (see Furuta et al). 2001;69:158-68  
 Kaneko S (see Tanaka et al). 2001;69:108-13  
 Kaplan B (see Kovarik et al). 2001;69:48-56  
 Kaszkin M (see Loew et al). 2001;69:356-64  
 Katzir I (see Halkin et al). 2001;69:260-5  
 Kawaguchi A (see Harada et al). 2001;69:130-6  
 Kawaguchi A (see Tsuruoka et al). 2001;69:422-30  
 Kawaguchi A, Sugimoto K, Ohmori M, Tsuruoka S, Harada K, Kitoh Y, Kobayashi E, Fujimura A. Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology. 2001;69:232-7  
 Kessler DK (see Kessler and Kessler). 2001;69:1-6  
 Kessler KM, Kessler DK. Definition and axioms of net treatment benefit. 2001;69:1-6 (Commentary)  
 Kiltgaard NA (see Madsen et al). 2001;69:41-7  
 Kim RB (see Stein et al). 2001;69:317-23  
 Kitoh Y (see Kawaguchi et al). 2001;69:232-7  
 Kivistö KT (see Kyrklund et al). 2001;69:340-5  
 Kivistö KT (see Niemi et al). 2001;69:194-200  
 Kivistö KT (see Niemi et al). 2001;69:400-6  
 Klitgaard NA (see Enggaard et al). 2001;69:245-51  
 Kobayashi E (see Kawaguchi et al). 2001;69:232-7  
 Kobayashi S (see Tateishi et al). 2001;69:333-9  
 Korn A (see Kovarik et al). 2001;69:201-9  
 Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first

- post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. 2001;69:48-56
- Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML, Korn A. Simulect Liver Transplant Study Group. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. 2001;69:201-9
- Krishen A (see Gonzales et al). 2001;69:438-44
- Kubli S, Feihl F, Waechter B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. 2001;69:238-44
- Kühlkamp V (see Busse et al). 2001;69:324-32
- Kurihara S (see Tsuruoka et al). 2001;69:422-30
- Kurman I (see Halkin et al). 2001;69:260-5
- Kuroiwa Y (see Nakajima et al). 2001;69:72-8
- Kustra RP (see Gonzales et al). 2001;69:438-44
- Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. 2001;69:104-7
- Kwon JT (see Nakajima et al). 2001;69:72-8
- Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. 2001;69:340-5

## L

- Lacoste-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Bégaud B. Incidence of serious adverse drug reactions in general practice: a prospective study. 2001;69:458-62
- Lagnaoui R (see Moore et al). 2001;69:445-50
- Laitila J (see Kyrklund et al). 2001;69:340-5
- Laitila J (see Niemi et al). 2001;69:194-200
- Lauffer G (see Weigel et al). 2001;69:137-44
- Lee KH (see Yu et al). 2001;69:266-73
- Lehr S (see Schenk et al). 2001;69:365-71
- Lesko LJ (see Galuppi et al). 2001;69:387-99
- Liu SS, Hodgson PS, Carpenter RL, Fricke JR, Jr, ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. 2001;69:66-71
- Loew D, Möllerfield J, Schröder A, Puttkammer S, Kaszkin M. Investigations on the pharmacokinetic properties of *Harpagophytum* extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. 2001;69:356-64
- Lorber M (see Kovarik et al). 2001;69:48-56
- Lunell E (see Molander et al). 2001;69:57-65
- Lusawska-Kutrzeba T (see Gawrońska-Szklarz et al). 2001;69:372-78

## M

- Madsen H, Enggaard TP, Hansen LL, Kiltgaard NA, Brøsen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. 2001;69:41-7
- Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. 2001;69:14-23
- Malkin BBO (see Halkin et al). 2001;69:260-5
- Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. 2001;69:24-31
- Manion CV, Howard J, Ogle B, Parkhurst J, Edmundson A. Aspartame effect in sickle cell anemia. 2001;69:346-55
- Mashimo K (see Kusumoto et al). 2001;69:104-7
- Masuda S (see Hashida et al). 2001;69:308-16

- Meier PJ (see Fattinger et al). 2001;69:223-31
- Meisel C (see Cascorbi et al). 2001;69:169-74
- Melikian AP (see Saul et al). 2001;69:145-57
- Metz A (see Gonzales et al). 2001;69:438-44
- Miremont G (see Lacoste-Roussillon et al). 2001;69:458-62
- Mizorogi Y (see Tateishi et al). 2001;69:333-9
- Molander L, Hansson A, Lunell E. Pharmacokinetics of nicotine in healthy elderly people. 2001;69:57-65
- Möllerfield J (see Loew et al). 2001;69:356-64
- Moore N, Pierfitte C, Pehourcq F, Lagnaoui R, Bégaud B. Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects. 2001;69:445-50
- Mörke K (see Busse et al). 2001;69:324-32
- Mould D, Chapelsky M, Aluri J, Swagdzis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. 2001;69:210-22
- Mueller MM (see Weigel et al). 2001;69:137-44
- Murray JJ (see Stein et al). 2001;69:317-23

## N

- Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. 2001;69:72-8
- Nakura H (see Tateishi et al). 2001;69:333-9
- Nashan B (see Kovarik et al). 2001;69:201-9
- Neuhaus P (see Kovarik et al). 2001;69:201-9
- Neuvonen M (see Kyrklund et al). 2001;69:340-5
- Neuvonen M (see Niemi et al). 2001;69:194-200
- Neuvonen M (see Niemi et al). 2001;69:400-6
- Neuvonen PJ (see Kyrklund et al). 2001;69:340-5
- Neuvonen PJ (see Niemi et al). 2001;69:194-200
- Neuvonen PJ (see Niemi et al). 2001;69:400-6
- Nides MA (see Gonzales et al). 2001;69:438-44
- Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. 2001;69:194-200
- Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. 2001;69:400-6
- Nishihori T (see Kusumoto et al). 2001;69:104-7
- Nishiki K (see Tsuruoka et al). 2001;69:422-30

## O

- Oda A (see Kusumoto et al). 2001;69:104-7
- Offen WW (see Goldstein et al). 2001;69:7-13
- Ogle B (see Manion et al). 2001;69:346-55
- Ohashi K (see Furuta et al). 2001;69:158-68
- Ohkubo T (see Tanaka et al). 2001;69:108-13
- Ohmori M (see Harada et al). 2001;69:130-6
- Ohmori M (see Kawaguchi et al). 2001;69:232-7
- Osono E (see Tsuruoka et al). 2001;69:422-30
- Otani K (see Tanaka et al). 2001;69:108-13

## P

- Paine MF (see Malhotra et al). 2001;69:14-23
- Pantze M (see Fattinger et al). 2001;69:223-31
- Park JY (see Yu et al). 2001;69:266-73
- Park SS (see Yu et al). 2001;69:266-73
- Parkhurst J (see Manion et al). 2001;69:346-55
- Pawlik A (see Gawrońska-Szklarz et al). 2001;69:372-78

- Peck CC (*see* Galuppi et al). 2001;69:387-99  
 Pediatric Sotalol Investigators (*see* Saul et al). 2001;69:145-57  
 Pehourcq F (*see* Moore et al). 2001;69:445-50  
 Penning-van Beest FJA, van Meegen E, Rosendaal FR, Stricker BH.  
 Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. 2001;69:451-7  
 Perneger TV (*see* Eitter and Perneger). 2001;69:175-83  
 Pierfitte C (*see* Moore et al). 2001;69:445-50  
 Pouyanne P (*see* Lacoste-Roussillon et al). 2001;69:458-62  
 Puttkammer S (*see* Loew et al). 2001;69:356-64

## R

- Ragueneau I, Sao AB, Démolis JL, Darné B, Funck-Brentano C, Jaillon P. Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers. 2001;69:122-9  
 Reichen J (*see* Fattinger et al). 2001;69:223-31  
 Reidenberg JW. Clinical pharmacology: niche or panorama? And does it matter? 2001;69:385-6 (Commentary)  
 Reidenberg MM, Conner BA. Counterfeit and substandard drugs. 2001;69:189-93 (Commentary)  
 Rogge MC (*see* Galuppi et al). 2001;69:387-99  
 Roots I (*see* Cascorbi et al). 2001;69:169-74  
 Rordorf C (*see* Kovarik et al). 2001;69:48-56  
 Rosendaal FR (*see* Penning-van Beest et al). 2001;69:451-7  
 Roskos LK (*see* Galuppi et al). 2001;69:387-99  
 Ross B (*see* Saul et al). 2001;69:145-57  
 Rouilly M (*see* Kovarik et al). 2001;69:48-56  
 Ryokawa Y (*see* Tanaka et al). 2001;69:108-13

## S

- Sadeque AJ (*see* Stein et al). 2001;69:317-23  
 Saito H (*see* Hashida et al). 2001;69:308-16  
 Saito T (*see* Tsuruoka et al). 2001;69:422-30  
 Salazar DE (*see* Abernethy et al). 2001;69:95-103  
 Samuels R (*see* Mould et al). 2001;69:210-22  
 Sao AB (*see* Ragueneau et al). 2001;69:122-9  
 Saul JP, Ross B, Schaffer MS, Beerman L, Melikian AP, Shi J, Williams J, Barbey JT, Jin J, Hinderling PH. Pediatric Sotalol Investigators. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. 2001;69:145-57  
 Säwe J (*see* Böttiger et al). 2001;69:32-40  
 Schaeffeler E (*see* Cascorbi et al). 2001;69:169-74  
 Schaffer MS (*see* Saul et al). 2001;69:145-57  
 Schenk P, Vonbank K, Schnack B, Haber P, Lehr S, Smetana R. Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study. 2001;69:365-71  
 Schnack B (*see* Schenk et al). 2001;69:365-71  
 Schoemaker C (*see* Twiss et al). 2001;69:431-7  
 Schrödter A (*see* Loew et al). 2001;69:356-64  
 Schwab M (*see* Cascorbi et al). 2001;69:169-74  
 Segall N (*see* Gonzales et al). 2001;69:438-44  
 Shi J (*see* Saul et al). 2001;69:145-57  
 Shin SG (*see* Yu et al). 2001;69:266-73  
 Shirai H (*see* Tateishi et al). 2001;69:333-9  
 Shirai N (*see* Furuta et al). 2001;69:158-68  
 Siegmund W. Reply. 2001;69:80-1 (Letter)  
 Simulect Liver Study Transplant Group (*see* Kovarik et al). 2001;69:201-9  
 Sindrup SH (*see* Enggaard et al). 2001;69:245-51  
 Smetana R (*see* Schenk et al). 2001;69:365-71  
 Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJJ. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. 2001;69:317-23

- Stieger B (*see* Fattinger et al). 2001;69:223-31  
 Stricker BH (*see* Penning-van Beest et al). 2001;69:451-7  
 387-99 G. Limited sampling approach. 2001;69:463 (Letter)  
 Sugawara K (*see* Tanaka et al). 2001;69:108-13  
 Sugimoto K (*see* Harada et al). 2001;69:130-6  
 Sugimoto K (*see* Kawaguchi et al). 2001;69:232-7  
 Sugimoto K (*see* Tsuruoka et al). 2001;69:422-30  
 Sugimura H (*see* Furuta et al). 2001;69:158-68  
 Sundell KL (*see* Goldstein et al). 2001;69:7-13  
 Suzuki A (*see* Tanaka et al). 2001;69:108-13  
 Swagdzis J (*see* Mould et al). 2001;69:210-22  
 Sweeney A (*see* Gonzales et al). 2001;69:438-44

## T

- Takashima M (*see* Furuta et al). 2001;69:158-68  
 Takata S (*see* Tsuruoka et al). 2001;69:422-30  
 Takaya K (*see* Kusumoto et al). 2001;69:104-7  
 Takeda K (*see* Kusumoto et al). 2001;69:104-7  
 Tanaka K (*see* Hashida et al). 2001;69:308-16  
 Tanaka K (*see* Kusumoto et al). 2001;69:104-7  
 Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizake T. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. 2001;69:108-13  
 Tanaka N (*see* Nakajima et al). 2001;69:72-8  
 Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. 2001;69:333-9  
 Thummel KE (*see* Tateishi et al). 2001;69:333-9  
 Tollemar J (*see* Böttiger et al). 2001;69:32-40  
 Tsuruoka S, Osono E, Nishiki K, Kawaguchi A, Arai T, Furuyoshi S, Saito T, Takata S, Sugimoto K, Kurihara S, Fujimura A. Removal of digoxin by column for specific adsorption of  $\beta_2$ -microglobulin: a potential use for digoxin intoxication. 2001;69:422-30  
 Tsuruoka S (*see* Kawaguchi et al). 2001;69:232-7  
 Twiss IM, Burggraaf J, Schoemaker C, van Elburg RM, den Hartigh J, Cohen AF, Vermeij P. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. 2001;69:431-7

## U

- Uemoto S (*see* Hashida et al). 2001;69:308-16  
 Ueno K (*see* Kusumoto et al). 2001;69:104-7

## V

- van Elburg RM (*see* Twiss et al). 2001;69:431-7  
 van Meegen E (*see* Penning-van Beest et al). 2001;69:451-7  
 Vermeij P (*see* Twiss et al). 2001;69:431-7  
 Vonbank K (*see* Schenk et al). 2001;69:365-71

## W

- Waeber B (*see* Kubli et al). 2001;69:238-44  
 Wandel C (*see* Stein et al). 2001;69:317-23  
 Watanabe M (*see* Tateishi et al). 2001;69:333-9  
 Watkins PB (*see* Malhotra et al). 2001;69:14-23  
 Webb D (*see* Clive et al). 2001;69:252-9  
 Weber C (*see* Fattinger et al). 2001;69:223-31  
 Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. 2001;69:137-44

Wilkinson GR (*see* Tateishi et al). 2001;69:333-9  
Williams J (*see* Saul et al). 2001;69:145-57  
Winkler M (*see* Kovarik et al). 2001;69:48-56  
Wood AJJ (*see* Stein et al). 2001;69:317-23  
Wrześniewska J (*see* Gawrońska-Szklarz et al). 2001;69:372-78  
Wu TC (*see* Chiou et al). 2001;69:79-80 (Letter)

X

Xiao F (*see* Furuta et al). 2001;69:158-68

Y

Yamamoto H (*see* Nakajima et al). 2001;69:72-8  
Yamamoto T (*see* Nakajima et al). 2001;69:72-8

Yamamoto Y (*see* Nakajima et al). 2001;69:72-8  
Yamazaki H (*see* Nakajima et al). 2001;69:72-8  
Yi SY (*see* Yu et al). 2001;69:266-73  
Yim DS (*see* Yu et al). 2001;69:266-73  
Yokoi T (*see* Nakajima et al). 2001;69:72-8  
Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang JJ, Yi SY, Bae KS, Shin SG. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. 2001;69:266-73

Z

Zenta T (*see* Nakajima et al). 2001;69:72-8  
Zimmerman JJ (*see* Böttiger et al). 2001;69:32-40  
Zuckermann AO (*see* Weigel et al). 2001;69:137-44

## Subject index\*

### A

#### Acenocoumarol

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs (Penning-van Beest et al). 2001;69:451-7

#### Acetylcholine

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation (Kubli et al). 2001;69:238-44

#### Acetyltransferases

Genotype of *N*-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy (Gawronska-Szklar et al). 2001;69:372-78

#### ADL 8-2698

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia (Liu et al). 2001;69:66-71

#### Adverse drug reactions

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions (Fattinger et al). 2001;69:223-31

Incidence of serious adverse drug reactions in general practice: a prospective study (Lacoste-Roussillon et al). 2001;69:458-629

#### Age factors

The effect of rifampin administration on the disposition of fexofenadine (Hamman et al). 2001;69:114-21

Pharmacokinetics of nicotine in healthy elderly people (Molander et al). 2001;69:57-65

#### Aged

Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects (Moore et al). 2001;69:445-50

Pharmacokinetics of nicotine in healthy elderly people (Molander et al). 2001;69:57-6

#### Alzheimer's disease

Galantamine hydrobromide (USAN List No. 438). 2001;69:464

Galantamine (USAN List No. 438). 2001;69:466

#### Amdray™

Valspodar (USAN List No. 438). 2001;69:465

#### Amlodipine

Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers (Ragueneau et al). 2001;69:122-9

#### Amoxicillin

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al). 2001;69:158-68

#### Analgesics

Parecoxib (USAN List No. 435). 2001;69:186

Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans (Enggaard et al). 2001;69:245-51

#### Anemia, sickle cell

Aspartame effect in sickle cell anemia (Manion et al). 2001;69:346-55

#### Angiotensin II

Effect of angiotensin II on venodilator response to nitroglycerin (Harada et al). 2001;69:130-6

#### Anti-asthmatic agents

Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study (Schenk et al). 2001;69:365-71

#### Antibiotics

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs (Penning-van Beest et al). 2001;69:451-7

Sitafloxacin (USAN List No. 436). 2001;69:277

#### Anticoagulants

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs (Penning-van Beest et al). 2001;69:451-7

#### Anticonvulsants

Ganaxolone (USAN List No. 438). 2001;69:466

Rufinamide (USAN List No. 435). 2001;69:187

#### Antihypertensives

Gemopatrilat (USAN List No. 438). 2001;69:465

#### Anti-inflammatory agents

Investigations on the pharmacokinetic properties of *Harpagophytum* extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo (Loew et al). 2001;69:356-64

Parecoxib (USAN List No. 435). 2001;69:186

Pimecrolimus (USAN List No. 437). 2001;69:380

#### Antilipemic agents

Rosuvastatin (USAN List No. 436). 2001;69:276

#### Antineoplastic agents

Cetorelix acetate (USAN List No. 437). 2001;69:380

Tezacitabine (USAN List No. 436). 2001;69:277

Tridolgosir hydrochloride (USAN List No. 435). 2001;69:186

Triptorelin pamoate (USAN List No. 436). 2001;69:275

Valspodar (USAN List No. 438). 2001;69:465

#### Antiviral agents

Fosamprenavir calcium (USAN List No. 435). 2001;69:187

Fosamprenavir sodium (USAN List No. 437). 2001;69:379

Omaciclovir (USAN List No. 434). 2001;69:84

Valomaciclovir stearate (USAN List No. 436). 2001;69:276

#### Aspartame

Aspartame effect in sickle cell anemia (Manion et al). 2001;69:346-55

#### Atenolol

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation (Kubli et al). 2001;69:238-44

#### Atrial fibrillation

Disposition and pharmacologic effects of *R/S*-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing (Busse et al). 2001;69:324-32

### B

#### Basiliximab

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation (Kovarik et al). 2001;69:201-9

#### Benzodiazepines

Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects (Moore et al). 2001;69:445-50

\*January, pp. 1-88; February, pp. P1-P128; March, pp. 89-188; April, pp. 189-280; May, pp. 281-384; June, pp. 385-482. Index to the ASCPT meeting abstracts is located in the February issue.



**Bezafibrate**

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate (Kyrklund et al), 2001:69:340-5

**Biological markers**

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework (Biomarkers Definitions Working Group), 2001:69:89-95 (Commentary)

**Blood-brain barrier**

Limited sampling approach (Suarez-Kurtz), 2001:69:463 (Letter)

**Bosentan**

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions (Fattinger et al), 2001:69:223-31

**Brain injuries**

Traxoprodil mesylate (USAN List No. 435), 2001:69:185

**Bronchial hyperreactivity**

Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study (Schenk et al), 2001:69:365-71

**Bupropion**

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study (Gonzales et al), 2001:69:438-44

**C**

**Capromorelin tartrate**

Capromorelin tartrate (USAN List No. 435), 2001:69:186

**Caucasians**

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects (Cascorbi et al), 2001:69:169-74

**Cerebrospinal fluid**

Limited sampling approach (Suarez-Kurtz), 2001:69:463 (Letter)

**Cerebrovascular disorders**

Traxoprodil mesylate (USAN List No. 435), 2001:69:185

**Cetorelix acetate**

Cetorelix acetate (USAN List No. 437), 2001:69:380

**Children**

Genotype of *N*-acetyltransferase 2 (*NAT2*) polymorphism in children with immunoglobulin E-mediated food allergy (Gawronska-Szklarz et al), 2001:69:372-78  
Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia (Saul et al), 2001:69:145-57

**Cholinesterase inhibitors**

Galantamine hydrobromide (USAN List No. 438), 2001:69:464  
Galantamine (USAN List No. 438), 2001:69:466

**Choriogonadotropin alfa**

Choriogonadotropin alfa (USAN List No. 437), 2001:69:381

**Citrus**

Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins (Malhotra et al), 2001:69:14-23

**Clarithromycin**

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al), 2001:69:158-68

**Commentaries**

Being a modern pharmaceutical company: new paradigms for the pharmaceutical industry (Hassan), 2001:69:281-5  
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework (Biomarkers Definitions Working Group), 2001:69:89-95

Clinical pharmacology: niche or panorama? And does it matter? 2001:69:385-6

Counterfeit and substandard drugs (Reidenberg and Conner), 2001:69:189-93

Definition and axioms of net treatment benefit (Kessler and Kessler), 2001:69:1-6

Determination of pregnancy outcome risk rates after exposure to an intervention (Goldstein et al), 2001:69:7-13

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report (Galluppi et al) 2001:69:387-99

**Community pharmacy services**

Preventing drug interactions by online prescription screening in community pharmacies and medical practices (Halkin et al), 2001:69:260-5

**Congestive heart failure; see Heart failure, congestive**

**Contact lens material**

Ocufilcon F (USAN List No. 434), 2001:69:84

**Contraceptive agents**

Norelgestromin (USAN List No. 434), 2001:69:83

**Contrast media**

Palmitic acid (USAN List No. 434), 2001:69:83

**Cyclosporine**

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects (Stein et al), 2001:69:317-23

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine (Kovarik et al), 2001:69:48-56

**Cytochrome P450**

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe (Tateishi et al), 2001:69:333-9

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al), 2001:69:158-68

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 (Yu et al), 2001:69:266-73

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide (Madsen et al), 2001:69:41-7

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans (Nakajima et al), 2001:69:72-8

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin (Tanaka et al), 2001:69:108-13

**D**

**Developing countries**

Counterfeit and substandard drugs (Reidenberg and Conner), 2001:69:189-93 (Commentary)

**Diabetes mellitus**

Rivoglitazone (USAN List No. 435), 2001:69:185

**Digoxin**

An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol (Chiou et al), 2001:69:79-80 (Letter)

Removal of digoxin by column for specific adsorption of  $\beta_2$ -microglobulin: a potential use for digoxin intoxication (Tsuruoka et al), 2001:69:422-30

Reply (Siegmund), 2001:69:80-1 (Letter)

**Diltiazem**

Effect of angiotensin II on venodilator response to nitroglycerin (Harada et al), 2001:69:130-6

- Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers (Böttiger et al). 2001;69:32-40
- DNA polymerase inhibitors**  
Omaciclovir (USAN List No. 434). 2001;69:84  
Valomaciclovir stearate (USAN List No. 436). 2001;69:276
- DNA topoisomerase inhibitors**  
Sitafloxacin (USAN List No. 436). 2001;69:277
- Drug approval**  
Risks in new drug development: approval success rates for investigational drugs (DiMasi). 2001;69:297-307
- Drug development**  
Being a modern pharmaceutical company: new paradigms for the pharmaceutical industry (Hassan). 2001;69:281-5 (Commentary)  
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework (Biomarkers Definitions Working Group). 2001;69:89-95 (Commentary)  
Clinical pharmacology: niche or panorama? And does it matter? 2001;69:385-6 (Commentary)  
Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report (Galluppi et al) 2001;69:387-99 (Commentary)  
New drug development in the United States from 1963 to 1999 (DiMasi). 2001;69:286-96  
Risks in new drug development: approval success rates for investigational drugs (DiMasi). 2001;69:297-307
- Drug interactions; see also Food-drug interactions**  
Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs (Penning-van Beest et al). 2001;69:451-7  
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide (Niemi et al). 2001;69:400-6  
Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers (Böttiger et al). 2001;69:32-40  
Preventing drug interactions by online prescription screening in community pharmacies and medical practices (Halkin et al). 2001;69:260-5
- Drug therapy**  
Definition and axioms of net treatment benefit (Kessler and Kessler). 2001;69:1-6 (Commentary)  
Determination of pregnancy outcome risk rates after exposure to an intervention (Goldstein et al). 2001;69:7-13 (Commentary)
- Drug toxicity; see Adverse drug reactions**
- E**
- Editorials; see Commentaries**
- Education, medical**  
Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology (Kawaguchi et al). 2001;69:232-7
- Elderly; see Aged**
- Electrocardiography; see also QT intervals**  
Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia (Saul et al). 2001;69:145-57
- Epidemiology**  
Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects (Moore et al). 2001;69:445-50
- Erythrocytes**  
Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients (Weigel et al). 2001;69:137-44
- Esomeprazole magnesium**  
Esomeprazole magnesium (USAN List No. 438). 2001;69:464
- Ethnic factors; see also Race**  
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups (Mancinelli et al). 2001;69:24-31
- Everolimus**  
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine (Kovarik et al). 2001;69:48-56
- EVRA™; see Norelgestromin**
- Excipients**  
Fosvet (USAN List No. 437). 2001;69:379
- F**
- FDA; see United States Food and Drug Administration**
- Felodipine**  
Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins (Malhotra et al). 2001;69:14-23
- Females; see Gender factors**
- Fexofenadine**  
The effect of rifampin administration on the disposition of fexofenadine (Hamman et al). 2001;69:114-21
- Fibrinogen antagonists**  
Lamifiban hydrochloride (USAN List No. 434). 2001;69:82
- Fluconazole**  
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;69:194-200
- Fluvoxamine**  
Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men (Kusumoto et al). 2001;69:104-7  
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;69:194-200  
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide (Madsen et al). 2001;69:41-7
- Food hypersensitivity**  
Genotype of *N*-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy (Gawronska-Szklarz et al). 2001;69:372-78
- Fosamprenavir calcium**  
Fosamprenavir calcium (USAN List No. 435). 2001;69:187
- Fosamprenavir sodium**  
Fosamprenavir sodium (USAN List No. 437). 2001;69:379
- Fosvet**  
Fosvet (USAN List No. 437). 2001;69:379
- Fruit juices; see Citrus**
- Furocoumarins; see Psoralens**
- Furosemide**  
Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology (Kawaguchi et al). 2001;69:232-7
- G**
- Galantamine**  
Galantamine (USAN List No. 438). 2001;69:466
- Galantamine hydrobromide**  
Galantamine hydrobromide (USAN List No. 438). 2001;69:464
- Ganaxolone**  
Ganaxolone (USAN List No. 438). 2001;69:466
- Gastric acid secretion inhibitors**  
Esomeprazole magnesium (USAN List No. 438). 2001;69:464
- Gastrin-releasing peptide**  
Gastrin-releasing peptide is a potent vasodilator in humans (Clive et al). 2001;69:252-9



### Gastrointestinal tract

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia (Liu et al). 2001;69:66-71

The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate (Twiss et al). 2001;69:431-7

### Gemfibrozil

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate (Kyrklund et al). 2001;69:340-5

### Gemopatrilat

Gemopatrilat (USAN List No. 438). 2001;69:465

### Gender factors

The effect of rifampin administration on the disposition of fexofenadine (Hamman et al). 2001;69:114-21

### Genes, MDR

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects (Cascorbi et al). 2001;69:169-74

Pharmacokinetic and prognostic significance of intestinal *MDR1* expression in recipients of living-donor liver transplantation (Hashida et al). 2001;69:308-16

### Glimepiride

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;69:194-200

### Glipizide

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide (Niemi et al). 2001;69:400-6

### Globalization of industry

Being a modern pharmaceutical company: new paradigms for the pharmaceutical industry (Hassan). 2001;69:281-5 (Commentary)

### Glyburide

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide (Niemi et al). 2001;69:400-6  
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions (Fattinger et al). 2001;69:223-31

### Gonadotropin-releasing hormone antagonists

Iturelix (USAN List No. 434). 2001;69:83  
Triptorelin pamoate (USAN List No. 436). 2001;69:275

### Grapefruit juice; see Citrus

### Growth hormone deficiency

Capromorelin tartrate (USAN List No. 435). 2001;69:186

## II

### Harpagoside

Investigations on the pharmacokinetic properties of *Harpagophytum* extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo (Loew et al). 2001;69:356-64

### Headache; see Migraine

### Heart failure, congestive

Capromorelin tartrate (USAN List No. 435). 2001;69:186  
Gemopatrilat (USAN List No. 438). 2001;69:465

### Heart transplantation

Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients (Weigel et al). 2001;69:137-44

### Helicobacter pylori

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al). 2001;69:158-68

### Hemodialysis

Removal of digoxin by column for specific adsorption of  $\beta_2$ -microglobulin: a potential use for digoxin intoxication (Tsuruoka et al). 2001;69:422-30

### Hemoglobin

Aspartame effect in sickle cell anemia (Manion et al). 2001;69:346-55

### Hemorrhage

A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients (Mould et al). 2001;69:210-22

### Hepatic disease; see Liver diseases

### Hepatitis C

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C (Jen et al). 2001;69:407-21

### Herpes zoster

Valomaciclovir stearate (USAN List No. 436). 2001;69:276

### Hexadecanoic acid; see Palmitic acid

### Hydroxymethylglutaryl (HMG) CoA reductase inhibitors

Rosuvastatin (USAN List No. 436). 2001;69:27

### Hypoglycemic agents

Nateglinide (USAN List No. 434). 2001;69:82

## I

### Immunosuppressive agents

Pimecrolimus (USAN List No. 437). 2001;69:380  
Visilizumab (USAN List No. 436). 2001;69:277

### Indinavir

Limited sampling approach (Suarez-Kurtz). 2001;69:463 (Letter)

### Infants

Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia (Saul et al). 2001;69:145-57

### Infertility

Choriogonadotropin alfa (USAN List No. 437). 2001;69:381

### Inosine monophosphate (IMP) dehydrogenase

Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients (Weigel et al). 2001;69:137-44

### Interferon alfa-2b

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C (Jen et al). 2001;69:407-21

### Isomerism

Disposition and pharmacologic effects of *R/S*-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing (Busse et al). 2001;69:324-32

### Iturelix

Iturelix (USAN List No. 434). 2001;69:83

## J

### Japanese

Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men (Kusumoto et al). 2001;69:104-7

## K

### Kidney transplantation

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects (Stein et al). 2001;69:317-23  
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine (Kovarik et al). 2001;69:48-56

## L

**Lamifiban hydrochloride**

Lamifiban hydrochloride (USAN List No. 434). 2001;69:82

**Lansoprazole**

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al). 2001;69:158-68

**Letters**

An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol (Chiou et al). 2001;69:79-80 (Letter)  
Limited sampling approach (Suarez-Kurtz). 2001;69:463 (Letter)  
Reply (Siegmond). 2001;69:80-1 (Letter)

**Ligands**

Fosveset (USAN List No. 437). 2001;69:379

**Liver diseases**

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions (Fattinger et al). 2001;69:223-31

**Liver transplantation**

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation (Kovarik et al). 2001;69:201-9  
Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation (Hashida et al). 2001;69:308-16

**Loratadine**

Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation (Abernathy et al). 2001;69:95-103

**Losartan**

Effect of angiotensin II on venodilator response to nitroglycerin (Harada et al). 2001;69:130-6

**Lotrafiban**

A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients (Mould et al). 2001;69:210-22

**Lovastatin**

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate (Kyrklund et al). 2001;69:340-5

**Luteotropic hormone releasing hormone antagonists**

Cetorelix acetate (USAN List No. 437). 2001;69:380

## M

**Magnesium sulfate**

Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study (Schenk et al). 2001;69:365-71

**Males; see Gender factors****Markers; see Biological markers****Medicine, herbal**

Investigations on the pharmacokinetic properties of *Harpagophytum* extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo (Loew et al). 2001;69:356-64

**Men; see Gender factors****Mephenytoin**

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin (Tanaka et al). 2001;69:108-13

**Mexiletine**

Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men (Kusumoto et al). 2001;69:104-7

**Mibefradil**

Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers (Ragueneau et al). 2001;69:122-9

 **$\beta_2$ -microglobulin**

Removal of digoxin by column for specific adsorption of  $\beta_2$ -microglobulin: a potential use for digoxin intoxication (Tsuruta et al). 2001;69:422-30

**Midazolam**

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe (Tateishi et al). 2001;69:333-9

**Migraine**

Ganaxolone (USAN List No. 438). 2001;69:466  
Tidemberstat (USAN List No. 436). 2001;69:275

**Mirostipen**

Mirostipen (USAN List No. 435). 2001;69:187

**Moclobemide**

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 (Yu et al). 2001;69:266-73

**Monoclonal antibodies**

Visilizumab (USAN List No. 436). 2001;69:277

**Morphine**

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia (Liu et al). 2001;69:66-71

**Mycophenolate mofetil**

Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients (Weigel et al). 2001;69:137-44

**Myeloprotectant**

Mirostipen (USAN List No. 435). 2001;69:187

## N

**Nateglinide**

Nateglinide (USAN List No. 434). 2001;69:82

**Nebivolol**

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation (Kubli et al). 2001;69:238-44

**Nefazodone**

Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation (Abernathy et al). 2001;69:95-103

**Net treatment benefit**

Definition and axioms of net treatment benefit (Kessler and Kessler). 2001;69:1-6 (Commentary)

**Nexium™**

Esomeprazole magnesium (USAN List No. 438). 2001;69:464

**Nicotine**

Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public (Etter and Perneger). 2001;69:175-83

Pharmacokinetics of nicotine in healthy elderly people (Molander et al). 2001;69:57-65

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans (Nakajima et al). 2001;69:72-8

**Nicotine bitartrate**

Nicotine bitartrate (USAN List No. 434). 2001;69:84

**Nifedipine**

Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers (Ragueneau et al). 2001;69:122-9

**Nitric oxide**

Gastrin-releasing peptide is a potent vasodilator in humans (Clive et al). 2001;69:252-9

**Nitroglycerin**

Effect of angiotensin II on venodilator response to nitroglycerin (Harada et al). 2001;69:130-6

**Norelgestromin**

Norelgestromin (USAN List No. 434). 2001;69:83

**Nuvion™; see Visilizumab**

O

**Ocufilcon F**

Ocufilcon F (USAN List No. 434). 2001;69:84

**Omaciclovir**

Omaciclovir (USAN List No. 434). 2001;69:84

**Omeprazole**

Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin (Furuta et al). 2001;69:158-68

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 (Yu et al). 2001;69:266-73

**ORTHO EVRA™; see Norelgestromin**

**Ovidrel®**

Choriogonadotropin alfa (USAN List No. 437). 2001;69:381

P

**Pain; see also Analgesics**

Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans (Enggaard et al). 2001;69:245-51

**Palmitic acid**

Palmitic acid (USAN List No. 434). 2001;69:83

**Pamidronate**

The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate (Twiss et al). 2001;69:431-7

**Pamorelin; see Triptorelin pamoate**

**Pantoprazole**

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin (Tanaka et al). 2001;69:108-13

**Parecoxib**

Parecoxib (USAN List No. 435). 2001;69:186

**P-glycoprotein**

An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol (Chiou et al). 2001;69:79-80 (Letter)

Reply (Siegmund). 2001;69:80-1 (Letter)

**Pharmacology**

Clinical pharmacology: niche or panorama? And does it matter? 2001;69:385-6 (Commentary)

**Pharmacy services, hospital**

Preventing drug interactions by online prescription screening in community pharmacies and medical practices (Halkin et al). 2001;69:260-5

**Phenprocoumon**

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs (Penning-van Beest et al). 2001;69:451-7

**Pimecrolimus**

Pimecrolimus (USAN List No. 437). 2001;69:380

**Platelet aggregation**

A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients (Mould et al). 2001;69:210-22

**Polymers**

Ocufilcon F (USAN List No. 434). 2001;69:84

**Polymorphism (genetics)**

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 (Yu et al). 2001;69:266-73

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects (Casorbi et al). 2001;69:169-74

Genotype of *N*-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy (Gawronska-Szklarz et al). 2001;69:372-78

Relationship between interindividual differences in nicotine metabolism and *CYP2A6* genetic polymorphism in humans (Nakajima et al). 2001;69:72-8

**Polypeptides**

Iturelix (USAN List No. 434). 2001;69:83

Mirostipen (USAN List No. 435). 2001;69:187

Triptorelin pamoate (USAN List No. 436). 2001;69:275

**Population studies**

A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients (Mould et al). 2001;69:210-22

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation (Kovarik et al). 2001;69:201-9

Incidence of serious adverse drug reactions in general practice: a prospective study (Lacoste-Roussillon et al). 2001;69:458-62

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C (Jen et al). 2001;69:407-21

**Pregnancy**

Determination of pregnancy outcome risk rates after exposure to an intervention (Goldstein et al). 2001;69:7-13 (Commentary)

**Probenecid**

Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology (Kawaguchi et al). 2001;69:232-7

**Protease inhibitors**

Fosamprenavir calcium (USAN List No. 435). 2001;69:187

Fosamprenavir sodium (USAN List No. 437). 2001;69:379

**Proteins**

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report (Galluppi et al). 2001;69:387-99 (Commentary)

**Psoralens**

Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins (Malhotra et al). 2001;69:14-23

**Public health**

Incidence of serious adverse drug reactions in general practice: a prospective study (Lacoste-Roussillon et al). 2001;69:458-62

Q

**QT intervals**

Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation (Abernathy et al). 2001;69:95-103

**Quality control**

Counterfeit and substandard drugs (Reidenberg and Conner). 2001;69:189-93 (Commentary)

R

**Race; see also Caucasians; Ethnic factors**

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects (Stein et al). 2001;69:317-23

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe (Tateishi et al). 2001;69:333-9

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups (Mancinelli et al). 2001;69:24-31

**Reminyl™**

Galantamine hydrobromide (USAN List No. 438). 2001;69:464

Galantamine (USAN List No. 438). 2001;69:466

**Rifampin**

The effect of rifampin administration on the disposition of fexofenadine (Hamman et al). 2001;69:114-21

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide (Niemi et al). 2001;69:400-6

#### Risk assessment

Definition and axioms of net treatment benefit (Kessler and Kessler). 2001;69:1-6 (Commentary)

Determination of pregnancy outcome risk rates after exposure to an intervention (Goldstein et al). 2001;69:7-13 (Commentary)

Risks in new drug development: approval success rates for investigational drugs (DiMasi). 2001;69:297-307

#### Rivoglitazone

Rivoglitazone (USAN List No. 435). 2001;69:185

#### Rosuvastatin

Rosuvastatin (USAN List No. 436). 2001;69:276

#### Rufinamide

Rufinamide (USAN List No. 435). 2001;69:187

### S

#### Sirolimus

Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers (Böttiger et al). 2001;69:32-40

#### Sitafloxacin

Sitafloxacin (USAN List No. 436). 2001;69:277

#### Smoking cessation aids

Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public (Etter and Perneger). 2001;69:175-83

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study (Gonzales et al). 2001;69:438-44

Nicotine bitartrate (USAN List No. 434). 2001;69:84

#### Sotalol

Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia (Saul et al). 2001;69:145-57

#### Substandard and counterfeit drugs

Counterfeit and substandard drugs (Reidenberg and Conner). 2001;69:189-93 (Commentary)

#### Sugar absorption test

The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate (Twiss et al). 2001;69:431-7

#### Surrogate endpoints

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework (Biomarkers Definitions Working Group). 2001;69:89-95 (Commentary)

#### Surveys

Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public (Etter and Perneger). 2001;69:175-83

New drug development in the United States from 1963 to 1999 (DiMasi). 2001;69:286-96

### T

#### Tachycardia

Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia (Saul et al). 2001;69:145-57

#### Tacrolimus

Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation (Hashida et al). 2001;69:308-16

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups (Mancinelli et al). 2001;69:24-31

#### Talinolol

An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol (Chiou et al). 2001;69:79-80 (Letter)

Reply (Siegmund). 2001;69:80-1 (Letter)

#### Terfenadine

Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation (Abernathy et al). 2001;69:95-103

#### Tezacitabine

Tezacitabine (USAN List No. 436). 2001;69:277

#### Tidemberstat

Tidemberstat (USAN List No. 436). 2001;69:275

#### Tolbutamide

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide (Madsen et al). 2001;69:41-7

#### Traxoprodil

Traxoprodil mesylate (USAN List No. 435). 2001;69:185

#### Tridolgosir hydrochloride

Tridolgosir hydrochloride (USAN List No. 435). 2001;69:186

#### Triptorelin pamoate

Triptorelin pamoate (USAN List No. 436). 2001;69:275

### U

#### United States Food and Drug Administration

New drug development in the United States from 1963 to 1999 (DiMasi). 2001;69:286-96

### V

#### Valspodar

Valspodar (USAN List No. 438). 2001;69:465

#### Valomaciclovir stearate

Valomaciclovir stearate (USAN List No. 436). 2001;69:276

#### Vasodilation

Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation (Kubli et al). 2001;69:238-44

Effect of angiotensin II on venodilator response to nitroglycerin (Harada et al). 2001;69:130-6

Gastrin-releasing peptide is a potent vasodilator in humans (Clive et al). 2001;69:252-9

#### Venlafaxine

Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans (Enggaard et al). 2001;69:245-51

#### Verapamil

Disposition and pharmacologic effects of *R/S*-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing (Busse et al). 2001;69:324-32

#### Visilizumab

Visilizumab (USAN List No. 436). 2001;69:277

### W

#### Women; see Gender factors

